![](/img/cover-not-exists.png)
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Ravi Vij, David S. Siegel, Sundar Jagannath, Andrzej J. Jakubowiak, Alexander Keith Stewart, Kevin McDonagh, Nizar Bahlis, Andrew Belch, Lori A. Kunkel, Sandra Wear, Alvin F. Wong, Michael WangVolume:
158
Year:
2012
Language:
english
DOI:
10.1111/j.1365-2141.2012.09232.x
File:
PDF, 198 KB
english, 2012